Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 452 Show results per page	View Search Criteria \| Help With Results


1.		XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				ML18530 NCT00127933


2.		Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 and over				Pharmaceutical / Industry				XRP6976J_4001 NCT00280098

Last Modified: 6/7/2007 First Published: 2/1/2002


3.		Phase II/III Randomized Study of Docetaxel With or Without Oblimersen (Bcl-2 Antisense Oligonucleotide; G3139 ) in Patients With Previously Treated Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				GENTA-GN304 NCI-G01-2046, UCLA-0301058, NCT00030641


4.		Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Other				NBCG10 REK 378-04-03133, NMA 03-07568, NCT00201435


5.		Docetaxel in Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				XRP6976F/2503 NCT00261703

Last Modified: 5/3/2007 First Published: 1/1/1994


6.		Phase III Randomized Study of Mitoxantrone With or Without Docetaxel as First-Line Chemotherapy for Women With Poor Risk Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				80 and under				Other				GER-AIO-01/92 EU-93011, NCT00002544

Last Modified: 1/15/2008


7.		Phase III Randomized Study of Docetaxel Versus Paclitaxel in Women With Metastatic or Locally Advanced, Inoperable Adenocarcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				AVENTIS-56976-TAX-311 RP-56976-TAX-311, NCI-V95-0680, NCT00002662

Last Modified: 9/1/1995


8.		Phase III Randomized Study of TXT vs DOX as First-Line Chemotherapy for Locally Advanced and/or Metastatic Soft Tissue Sarcoma (Summary Last Modified 09/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75								EORTC-62941

Last Modified: 2/9/2008 First Published: 1/1/1996


9.		Phase III Randomized Study of Preoperative Doxorubicin and Cyclophosphamide (AC) Versus Preoperative AC Followed by Docetaxel Versus Preoperative AC and Postoperative Docetaxel in Women With Operable Carcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				NCI				NSABP-B-27 NCT00002707, NSABP-B-27

Last Modified: 8/1/1997


10.		Phase III Randomized Study of High-Dose vs Low-Dose Docetaxel vs Standard Chemotherapy with Vinorelbine or Ifosfamide for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy (Summary Last Modified 08/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				MSKCC-95088 RP-56976-TAX-320, NCI-V96-0830

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute